Expertise in
9
conditions

Dragana V. Lavrnic

6, Dr. Subotic Sr. Street, 11 000, 
Belgrade, SE, RS 
Expertise in
9
conditions
6, Dr. Subotic Sr. Street, 11 000, 
Belgrade, SE, RS 

Overview

Dragana Lavrnic practices practicing medicine in Belgrade, Serbia.

Lavrnic is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Myotonic Dystrophy, Myotonic Dystrophy Type 2, Paramyotonia Congenita, and Myasthenia Gravis.

They are actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 2 clinical trials.

Locations

6, Dr. Subotic Sr. Street, 11 000, Belgrade, SE, Serbia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Biological
Study Drug: HYQVIA
Study Phase: Phase 3
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
View 1 Less Clinical Trial

61 Total Publications

Risk factors for generalization of ocular myasthenia gravis.
Risk factors for generalization of ocular myasthenia gravis.
Journal: Indian journal of ophthalmology
Published: March 10, 2025

Frequently Asked Questions about Dragana V. Lavrnic

Is Dragana V. Lavrnic a top-rated expert for Myotonic Dystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dragana V. Lavrnic is classified as an Elite expert for Myotonic Dystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dragana V. Lavrnic participate in research or clinical trials?

Yes. Dragana V. Lavrnic has published 61 articles and abstracts on conditions like Myotonic Dystrophy. You can view a list of Dragana V. Lavrnic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lavrnic's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile